Advances in Tumor Immunology and Immunotherapy [electronic resource] / edited by Joseph D. Rosenblatt, Eckhard R. Podack, Glen N. Barber, Augusto Ochoa.
By: Rosenblatt, Joseph D [editor.].
Contributor(s): Podack, Eckhard R [editor.] | Barber, Glen N [editor.] | Ochoa, Augusto [editor.] | SpringerLink (Online service).
Material type:
BookSeries: Current Cancer Research: Publisher: New York, NY : Springer New York : Imprint: Springer, 2014Description: IX, 371 p. 35 illus., 29 illus. in color. online resource.Content type: text Media type: computer Carrier type: online resourceISBN: 9781461488095.Subject(s): Medicine | Oncology | Toxicology | Biomedicine | Cancer Research | Pharmacology/ToxicologyDDC classification: 614.5999 Online resources: Click here to access online
In:
Springer eBooksSummary: This volume explores recent advances in understanding of fundamental immunology and insights into the dynamic interactions between tumors and the immune system, that provide new opportunities for therapeutic intervention in cancer. Chapter topics include evolving paradigms in the innate and adaptive response, newly appreciated immunosuppressive mechanisms, and novel preclinical strategies for manipulation of the immune system for therapeutic benefit in cancer. In addition, recent successes in the clinic, and emerging opportunities are covered. Future possibilities, such as the use of antibody engineering, fusion proteins, and the retargeting of immune cells through T-cell receptor engineering are discussed by leaders in the field, focusing on recent clinical experience, promising technologies, and challenges to clinical success.
This volume explores recent advances in understanding of fundamental immunology and insights into the dynamic interactions between tumors and the immune system, that provide new opportunities for therapeutic intervention in cancer. Chapter topics include evolving paradigms in the innate and adaptive response, newly appreciated immunosuppressive mechanisms, and novel preclinical strategies for manipulation of the immune system for therapeutic benefit in cancer. In addition, recent successes in the clinic, and emerging opportunities are covered. Future possibilities, such as the use of antibody engineering, fusion proteins, and the retargeting of immune cells through T-cell receptor engineering are discussed by leaders in the field, focusing on recent clinical experience, promising technologies, and challenges to clinical success.
There are no comments for this item.